

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

PICCONE, L.

Atty. Ref.: 1303-138

Serial No. unknown

Group:

Filed: March 13, 2002

Examiner:

For: APPARATUS DESIGNED TO MODULATE THE NEUROVEGETATIVE SYSTEM AND INTEGRATE ITS ACTION WITH THAT OF THE CENTRAL NERVOUS SYSTEM; APPLICATIONS IN THE TREATMENT OF THE VASCULAR SYSTEM AND ORTHOPAEDIC DISORDERS

\* \* \* \* \*

March 13, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT**

In order to place the above-identified application in better condition for examination, please amend the application as follows:

**IN THE SPECIFICATION**

Please substitute the following paragraphs in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Page 1, before the first line, please insert as a separate paragraph:

This application is the US national phase of international application PCT/EP01/08756 filed 27 July 2001, which designated the US.

**IN THE CLAIMS**

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

3. (Amended) Apparatus as claimed in claim 1, wherein the voltage of the pulses applied is controlled by the patient/user by suitable means.

4. (Amended) Apparatus as claimed in claim 1, characterised in that it includes a pair of electrodes designed to transmit the said pulses, one of which can be applied to the motor point and the other to the muscle belly in the area to be treated.

5. (Amended) Apparatus as claimed in claim 1, characterised in that the said means designed to transmit the said pulses include devices able to vary the voltage, amplitude and frequency of the said pulses.

6. (Amended) Apparatus as claimed in claim 1, characterised in that it includes means designed to regulate the amplitude and frequency of the pulses, which said means are activated directly by the patient.

**PICCONE, L.**  
Serial No. **unknown**

17. (New) A method according to claim 16 wherein the patient is affected by a combination of vasculopathy and neuropathy .

18. (New) A method according to claim 17 wherein the patient is affected by diabetic food.

PICCONE, L.  
Serial No. **unknown**

ALL INFORMATION CONTAINED  
HEREIN IS UNCLASSIFIED

**REMARKS**

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is captioned "**Version With**  
**Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



Arthur R. Crawford  
Reg. No. 25,327

ARC:ecb  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

Page 1, before the first line, please insert as a separate paragraph:

This application is the US national phase of international application

PCT/EP01/08756 filed 27 July 2001, which designated the US.

**IN THE CLAIMS**

3. (Amended) Apparatus as claimed in ~~each of the preceding claims~~ 1,  
wherein the voltage of the pulses applied is controlled by the patient/user by  
suitable means.

4. (Amended) Apparatus as claimed in ~~each of the preceding claims~~ 1,  
characterised in  
that it includes a pair of electrodes designed to transmit the said pulses, one of  
which can be applied to the motor point and the other to the muscle belly in the  
area to be treated.

5. (Amended) Apparatus as claimed in ~~each of the preceding claims~~ 1,  
characterised in that the said means designed to transmit the said pulses include  
devices able to vary the voltage, amplitude and frequency of the said pulses.

**PICCONE, L.**  
Serial No. **unknown**

6. (Amended) Apparatus as claimed in each of the preceding claims 1,  
characterised in that it includes means designed to regulate the amplitude and  
frequency of the pulses, which said means are activated directly by the patient.

17. (New) A method according to claim 16 wherein the patient is affected by a  
combination of vasculopathy and neuropathy.

18. (New) A method according to claim 17 wherein the patient is affected by  
diabetic foot.